The profits of “Avalon Pharma” increased 21.3% to 79.85 million riyals in 2024

The profits of the Middle East Pharmaceutical Industries Company (Avalon Pharma) in 2024 increased by 21.3% to 79.85 million riyals, compared to 65.83 million riyals in 2023.
According to the company’s statement on Saudi Arabia’s circulation, this is mainly due to the strong growth in revenue and the improvement of the total margin of profit, resulting from diversification of products and benefiting from low costs due to the high production activity.
However, the growth of the total profit partially was affected by the rise in sales, distribution and public and administrative expenses, due to the continued investment of the company in marketing and sales activities, attracting talents and developing them, and other expenses related to supporting expansion and growth.